Dr. Sanjida Ahmed, Director of Research said now a days there is enough awareness among the people that Early detection of cancer is the only solution for cancer detection. Panel of cancer detection will diagnose gene mutation in early stage before it appears physically. It will help to reduce the number of cancer patients in future.
What is Cancersafe test?
It is a highly sophisticated blood test to detect early cancer. Tumor markers have long been used, either to screen for cancers or to monitor cancer treatments, to track and screen for recurrences. Cancersafe test uses a panel of 10/11 tumor markers (10 for women, 11 for men). Tumor markers are molecules appearing in the blood in relation to development of some of the most important cancers. Measurement or identification of tumor markers is useful, because it can detect substances in the blood in early stages, a signal that further medical attention is needed.
Cancersafe test can also be useful in follow-up if you are being treated for the illness. Variations of the tumor markers can be followed by regular tests. Slight to moderate increase may occur 6-12 months before clinical signs of relapse.
Who would perform the test?
Everybody, especially over 40, also young women, caring about breast and ovary. Perform it once a year, or more if required, building your baseline and data for future: your report (since handling all results) will include graphs, demonstrating the evolution of the 10 (or 11) tumor markers: any abnormal increases would be an indication for medical consultation and further investigation.
How to collect the samples?
A normal blood sample from the arm is all that is required. It is very convenient, non-invasive and easy to obtain.
How long?
Result and report is delivered, with comments (from 4 specialists), only two days after your serum specimen reaches the laboratory.
Tests options
• Panel for Women
• Panel for Men
Panel for Women
Everybody, specially over 40, even the young women, caring about breast and ovary should perform this test once a year. The result includes graphs demonstrating the evolution of the following tumor markers. This evolution should be highly considered for treatment and prognosis if the possibility of developing cancer is observed. CEA, CA15-3, CA19-9, CA125, CA72-4, AFP, BHCG, B2M, NSE, CYFRA21-1
Panel for Men
All men, over 40, should perform it once a year, or more if required. This panel covers a wide range of cancers which are common in men. The evolution of the following tumor markers are demonstrated to screen for developing cancers in men. CEA, CA19-9, CA125, CA72-4, PSA+ FPSA, AFP, BHCG, B2M, NSE, CYFRA 21-1
Browse
related articles
Posted by Medilyn Manibo, Assistant News Editor
